Display options
Cite
Ayadi N, Dörr J, Motamedi S, et al. Temporal visual resolution and disease severity in MS. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e492doi: 10.1212/NXI.0000000000000492.
Ayadi, N., Dörr, J., Motamedi, S., Gawlik, K., Bellmann-Strobl, J., Mikolajczak, J., Brandt, A. U., Zimmermann, H., & Paul, F. (2018). Temporal visual resolution and disease severity in MS. Neurology(R) neuroimmunology & neuroinflammation, 5(5), e492. https://doi.org/10.1212/NXI.0000000000000492
Ayadi, Noah, et al. "Temporal visual resolution and disease severity in MS." Neurology(R) neuroimmunology & neuroinflammation vol. 5,5 (2018): e492. doi: https://doi.org/10.1212/NXI.0000000000000492
Ayadi N, Dörr J, Motamedi S, Gawlik K, Bellmann-Strobl J, Mikolajczak J, Brandt AU, Zimmermann H, Paul F. Temporal visual resolution and disease severity in MS. Neurol Neuroimmunol Neuroinflamm. 2018 Aug 14;5(5):e492. doi: 10.1212/NXI.0000000000000492. eCollection 2018 Sep. PMID: 30175166; PMCID: PMC6117185.
Copy Download .nbib Format: NLM
Share it on

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 14;5(5):e492. doi: 10.1212/NXI.0000000000000492. eCollection 2018 Sep.

Temporal visual resolution and disease severity in MS.

Neurology(R) neuroimmunology & neuroinflammation

Noah Ayadi, Jan Dörr, Seyedamirhosein Motamedi, Kay Gawlik, Judith Bellmann-Strobl, Janine Mikolajczak, Alexander U Brandt, Hanna Zimmermann, Friedemann Paul

Affiliations

  1. Charité-Universitätsmedizin Berlin (N.A., J.D., S.M., K.G., J.B.-S., J.M., A.U.B., H.Z., F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center; Neurology Department (J.D.), Multiple Sclerosis Center, Oberhavel Clinic, Henningsdorf; Experimental and Clinical Research Center (J.B.-S., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Neurology (F.P.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.

PMID: 30175166 PMCID: PMC6117185 DOI: 10.1212/NXI.0000000000000492

Abstract

OBJECTIVE: To examine temporal visual resolution assessed as critical flicker frequency (CFF) in patients with MS and to investigate associations with visual system damage and general disability and cognitive function.

METHODS: Thirty-nine patients with MS and 31 healthy controls (HCs) were enrolled in this cross-sectional study and underwent CFF testing, high- and low-contrast visual acuity, alertness and information processing speed using the paced auditory serial addition task (PASAT), and retinal optical coherence tomography (OCT). In patients with MS, visual evoked potentials (VEPs) and Expanded Disability Status Scale (EDSS) scores were assessed.

RESULTS: CFF in patients with MS (mean ± SD: 40.9 ± 4.4 Hz) was lower than in HCs (44.8 ± 4.4 Hz,

CONCLUSION: CFF reduction in MS occurs independently of ON and structural visual system damage. Its association with the EDSS score and alertness suggests that CFF reflects global disease processes and higher cortical processing rather than focal optic nerve or retinal damage.

References

  1. Ann Neurol. 2005 Sep;58(3):383-91 - PubMed
  2. Brain. 1976 Jun;99(2):255-68 - PubMed
  3. PLoS One. 2013 Sep 09;8(9):e73990 - PubMed
  4. Br J Ophthalmol. 2012 Jan;96(1):62-7 - PubMed
  5. PLoS One. 2006 Dec 20;1:e28 - PubMed
  6. J Neurol Sci. 2015 Oct 15;357(1-2):235-9 - PubMed
  7. Ann Neurol. 2011 Feb;69(2):292-302 - PubMed
  8. Mult Scler. 2015 Feb;21(2):163-70 - PubMed
  9. Neurology. 2005 Mar 22;64(6):992-5 - PubMed
  10. J Psychol. 1949 Jul;28(1):223-33 - PubMed
  11. BMC Neurol. 2014 Feb 20;14:31 - PubMed
  12. J Exp Psychol. 1947 Aug;37(4):318-32 - PubMed
  13. Neurology. 2016 Jun 14;86(24):2303-9 - PubMed
  14. JAMA Neurol. 2018 Mar 1;75(3):287-295 - PubMed
  15. Arch Neurol. 1981 Nov;38(11):687-9 - PubMed
  16. J Hepatol. 2007 Jul;47(1):67-73 - PubMed
  17. Biomed Opt Express. 2013 Jun 14;4(7):1133-52 - PubMed
  18. Neuroimage. 2001 Jul;14(1 Pt 2):S76-84 - PubMed
  19. AMA Arch Neurol Psychiatry. 1957 Feb;77(2):134-9 - PubMed
  20. Brain. 1999 May;122 ( Pt 5):871-82 - PubMed
  21. BMJ. 2007 Oct 20;335(7624):806-8 - PubMed
  22. Percept Mot Skills. 1963 Feb;16:103-8 - PubMed
  23. PLoS One. 2012;7(4):e34823 - PubMed
  24. Hepatology. 2007 Apr;45(4):879-85 - PubMed
  25. Mult Scler. 2014 Nov;20(13):1678-85 - PubMed
  26. Neurology. 1983 Nov;33(11):1444-52 - PubMed
  27. Lancet Neurol. 2010 Sep;9(9):921-32 - PubMed
  28. Br Med J. 1973 Dec 15;4(5893):661-4 - PubMed
  29. Ann Neurol. 1991 Aug;30(2):213-5 - PubMed
  30. EPMA J. 2017 Jul 25;8(3):279-294 - PubMed
  31. Arch Neurol. 1979 May;36(5):292-5 - PubMed
  32. Percept Mot Skills. 1982 Jun;54(3 Pt 2):1079-82 - PubMed
  33. AMA Arch Neurol Psychiatry. 1955 Jun;73(6):663-77 - PubMed
  34. Curr Treat Options Neurol. 2017 Apr;19(4):15 - PubMed
  35. Mult Scler. 2010 Sep;16(9):1134-40 - PubMed
  36. J Physiol. 1984 Dec;357:219-40 - PubMed
  37. J Neurol Neurosurg Psychiatry. 1961 Aug;24:260-5 - PubMed

Publication Types